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ABSTRACT
The importance of tumor microenvironment (TME) as a relevant contributor 
to cancer progression and its role in the development of de novo resistance to 
targeted therapies has become increasingly apparent. However, the mechanisms 
of microenvironment-mediated drug resistance for nonspecific conventional 
chemotherapeutic agents, such as platinum compounds or antimetabolites, are still 
unclear.
Here we describe a mechanism induced by soluble factors released by carcinoma-
associated fibroblasts (CAFs) that induce the translocation of AKT, Survivin and P38 
to the nucleus of tumor cells. These changes are guided to ensure DNA repair and 
the correct entrance and exit from mitosis in the presence of chemotherapy. We 
used conditioned media (CM) from normal-colonic fibroblasts and paired CAFs to 
assess dose response curves of oxaliplatin and 5-fluorouracil, separately or combined, 
compared with standard culture medium. We also evaluated a colony-forming assay 
and cell death to demonstrate the protective role of CAF-CM. Immunofluorescence 
confirmed the translocation of AKT, P38 and Survivin to the nucleus induced by CAF-
soluble factors. We also have shown that STAT3 or P38 inhibition provides a promising 
strategy for overcoming microenvironment-mediated resistance. Conversely, 
pharmacologic AKT inhibition induces an antagonistic effect that relieves a cMET 
and STAT3-mediated compensatory feedback that might explain the failure of AKT 
inhibitors in the clinic so far.
INTRODUCTION
Colorectal cancer (CRC) is the fourth most 
prevalent cancer and the leading cause of cancer mortality 
worldwide [1], but its early diagnosis makes the disease 
one of the most curable cancers [2], at least in developed 
countries. Nevertheless, one of the main obstacles that 
patients have to deal with over the course of the disease is 
resistance to treatments.
Research into therapies against specific targets or 
signaling pathways is one of the pillars of current cancer 
research, although most tumors are still treated with 
conventional cytotoxic therapies. Drug resistance remains 
the main obstacle to the success of cytotoxic therapies 
[3]. As with many aspects of the tumorigenic process, 
most research on drug resistance has focused on the 
acquired resistance of malignant cells, which is basically 
limited to the reduction of an initial tumor burden, and 
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so fails to eradicate a sufficient number of cancer cells 
to prevent clinical recurrence. Despite the extensive use 
of chemotherapy, the specific mechanisms causing tumor 
regression or recurrence after treatment are poorly known.
Environment-mediated drug resistance is a form of 
de novo resistance in which tumor cells are transiently 
protected from drugs [4]. The elevated serum levels of 
several cytokines secreted mainly by CAFs, such as IL-8, 
IL-1β, VEGF, TNFα, IL-17 and IL-6, have a prognostic 
value and are also implicated in tumor aggressiveness and 
poor response to therapy [5]. Signaling events triggered 
by such stromal cytokines and growth factors may be 
involved in de novo resistance, contributing to the failure 
to eliminate minimal residual disease, resulting, after 
strong selective pressure of therapy, in the recruitment 
of cancerous cells with acquired-resistance phenotypes 
[6, 7]. This protective effect is not universal across tumor 
types and drugs [8]. The effect of the microenvironment 
on resistance to targeted therapies is easier to understand 
conceptually, since different soluble factors might 
activate signaling events converging in the same pathway 
downstream of the targeted molecule/receptor. However, 
the mechanisms of microenvironment-mediated drug 
resistance for nonspecific and pleiotropic conventional 
chemotherapeutic agents, such as platinum compounds 
and antimetabolites, are still unclear.
Here we explore how CAF-soluble factors contribute 
to CRC chemoresistance in the presence of antimetabolites 
and DNA-damaging agents, like 5-fluorouracil (5FU), 
oxaliplatin (L-OHP). To this end, we decided to investigate 
multiple signaling pathways that may be involved in 
mediating resistance and that might offer a useful approach 
to identifying and describing some cellular and molecular 
alterations in the CRC chemoresistance process. We also 
examined how colorectal cancer cells may be sensitized to 
chemotherapy, in order to overcome the chemoresistance 
induced by CAFs.
RESULTS
Altered chemosensitivity of colorectal cancer 
cells after continuous exposure to chemotherapy 
in the presence of conditioned media from CAFs
We checked whether CAF-soluble factors influenced 
the chemosensitivity of different colorectal cancer 
cell lines with different genetic backgrounds to the 
conventional anticancer drugs oxaliplatin and 5FU. We 
obtained the IC50 after 96 hours of continuous exposure 
to drugs in the presence of standard culture medium 
(DMEMF12) or conditioned medium (CM) from normal 
colonic fibroblasts (NCFs) or paired CAFs. As illustrated 
in Figure 1a, for all cell lines tested, CM from CAFs 
(CAF-CM) conferred a survival advantage on the two 
anticancer agents separately in relation to DMEMF12, and 
in combination (FUOX; Figure 1b).
In addition, as shown in Figure 1c (top panel), the 
degree of protection conferred by CAF-soluble factors 
is variable, and it will probably depend on the capacity 
of each CAF to secrete protective factors, suggesting a 
certain degree of CAF heterogeneity that we [9] and others 
[10] have previously reported.
We suspected that such a protective effect might 
be a consequence of a slower proliferative capacity of 
cell lines in the presence of CAF-CM, as depicted in 
Figure 1c (lower panel; wst-1 assay), an observation 
already reported by us [11] and corroborated in Figure 1d 
(microphotography and hemocytometer counts).
Regarding the colony-forming assay, such 
differential proliferative rates were also observed (bigger 
colonies in DMEMF12) when cells were cultured in the 
absence of drugs (Figure 1e, left plates), while the number 
of colonies (>50 cells) was similar for both conditions 
(DMEMF12 and CM). Conversely, CAF-CM clearly 
stimulated the formation of colonies in the presence 
of 5FU and, to a lesser extent, for oxaliplatin or the 
combination (FUOX).
Additionally, CAFs were capable of inducing 
chemoresistance even when they were also exposed to 
chemotherapy in a 24-well Transwell coculture system, as 
depicted in Figure 1f: the more fibroblasts that interact in 
the coculture, the more protection was observed for tumor 
cells, suggesting that higher concentrations of soluble 
factors can induce more protection.
Cell death assessment and cell cycle phase 
distribution of CRC cells cultured with CAF-CM 
or DMEMF12 in the presence of oxaliplatin or 
5FU
We first assessed the capacity of CAF-soluble 
factors to diminish the apoptotic rates of colorectal cancer 
cells lines. Surprisingly, all the cell lines tested displayed 
a very low percentage of cells in apoptosis when exposed 
to 5FU or oxaliplatin at corresponding IC50 doses 
(Supplementary Figure S1), as reported by other authors 
[12, 13]. Remarkably, the apoptotic rate was slightly 
lower even than under basal conditions, suggesting that, 
although CAF-soluble factors reduce apoptosis in tumor 
cells, the mechanism of cell death is something other than 
apoptosis. Another factor that attracted our attention was 
the presence of swollen cells, particularly in the presence 
of 5FU, that despite also being reduced with respect to the 
entire population occur in a lower percentage in CAF-CM 
than in DMEMF12 for both treatments (Supplementary 
Figure S1). This is probably due to some cells dying by 
the process of oncosis, which is characterized by nuclear 
and cytoplasmic swelling. Nevertheless, the total number 
of oncotic or apoptotic cells was low when exposed to 
IC50 values of both drugs, suggesting a different type of 
cell death or a delayed or asynchronous process. Thus, we 
evaluated the total population of dead cells (PI staining) 
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Figure 1: a. Dose-response curves of different colorectal cell lines for oxaliplatin and 5FU after 96 hours in culture in standard medium 
(DMEMF12), conditioned medium (CM) from normal colonic fibroblasts (NCFs) or conditioned medium from carcinoma-associated 
fibroblasts (CM-CAF). Values of P<0.05 were considered statistically significant (sum of squares F-test for LogIC50. b. Dose-response 
curves of DLD-1 cells (left panel) and HT29 cells (right panel) for the combination of 5FU and oxaliplatin (FUOX) cultured with DMEMF12 
(control) or CAF-CM. c. Dose-response curves of DLD-1 cells cultured with different CAF-CM. The degree of protection conferred by 
CAFs is variable, probably depending on the ability to secrete particular cytokines/soluble factors that induce chemoprotection. This 
effect might be associated with the proliferative rate of cells in the different CMs, as depicted in the histograms in the absence of drugs 
(lower panel). d. This fact was confirmed by means ofa hemocytometer count (lower panel) after 4 days in culture, as depicted in the 
microphotograph. e. A similar diminished proliferative rate was also observed by means of a colony formation assay in the absence of 
drugs. However, the protective effect of CAF CM on HT29 cells was apparent after the addition of oxaliplatin and 5FU, separately or 
in combination. f. The protective effect might be involved in the concentration of the soluble factors responsible for such effect, since 
increasing quantities of fibroblasts increased the viability of tumor cells in a Transwell coculture proliferation assay. In addition, CAFs can 
induce such an effect in the presence of chemotherapy.
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for a longer exposure to 2× or 4× IC50 values for 5FU and 
L-OHP. As illustrated in Table 1, after 48 hours continuous 
exposure to 5FU or oxaliplatin, both cell types (HT29 and 
DLD-1) exhibited relatively low levels of PI-positive 
cells to a similar extent for CAF-CM and DMEMF12, 
even with a 4× IC50 drug concentration. However, the 
protective effect of CAF-CM was observed after extending 
the assay time until 120 hours of continuous exposure to 
drugs (HT29 cells) or even longer periods (168 hours for 
DLD-1 cells).
Given the long time required for effective cell death 
observed in previous experiments we aimed to evaluate 
the proportion of cells in each cell cycle phase to assess 
the effect of CAF-CM on the cell cycle perturbation 
induced by L-OHP or 5FU. Results are illustrated in 
Supplementary Table S1, confirming a less number of cells 
accumulated in S-phase and G2/M for 5FU and L-OHP 
respectively for HT29 cells and fewer cells in aneuploidy 
for DLD-1 cells, interline variation already reported for 
antimitotic drugs [14]. Interestingly, CAF-CM induced 
an accumulation of cells in G0G1, suggesting a prolonged 
G1 transit, in concordance with the lower proliferative 
capacity observed.
CHK2 is overstimulated in colorectal cancer cell 
lines cultured with CAF-conditioned media
The absence of apoptosis and the prolonged time 
needed to observe moderate levels of necrosis suggested 
that cells could be arrested at the point of entering mitosis 
with or without repairing the DNA damage induced by 
oxaliplatin and 5FU. CHK2 provides a survival signal 
for tumor cells when exposed to DNA damaging agents 
[15], especially for those inducing DSB, like doxorubicin, 
cisplatin [16], oxaliplatin and 5FU [17, 18] and is a key 
protein for DNA repair mediating BRCA2 phosphorilation 
that leads to disruption of RAD51-BRCA2 complex and 
then DSB repair. CHK2 has also been involved in base 
excision repair. In addition, CHK2 is an essential protein 
for maintaining genome integrity and is involved in the 
control of mitosis progression and repression of cell 
death during mitosis. Thus, we hypothesize that during 
mitosis CAF-soluble factors might mitigate the mitotic 
catastrophe induced by the drugs activating CHK2 for the 
proper control of the G2/M checkpoint. We observed a 
higher level of Thr68 phosphorylation of CHK2 in DLD-
1 cells cultured in CAF-CM compared with standard 
DMEMF12 after long-term exposure (24 hours and 
48 hours) to 5FU and oxaliplatin, as depicted in Figure 
2a. We corroborated the results using a P53 wt cell line 
(HCT116; Figure 2b). Thus, soluble factors secreted by 
CAFs might induce CHK2-mediated cell cycle arrest 
before entering mitosis in order to ensure DNA repair, 
thereby preparing cells for correct cell division. Higher 
levels of Aurora B in CAF CM also points to a correct 
mitosis in such conditions, particularly for 5FU treatment, 
where there was a statistically significant increase of 
AURKB positive cells (P<0.0001) and overexpression for 
L-OHP (Supplementary figure S2).
The mechanisms by which cells are able to restart 
the cell cycle and enter mitosis after the activation of 
the G2/M checkpoint seem to be regulated by CDC25 
phosphatases, in particular CDC25B. The latter is an 
essential protein that enables a cell to resume the cell cycle 
after DNA damage-induced cell cycle arrest [19]. When 
we examined the expression of CDC25B we observed 
overexpression of the phosphatase in cells cultured in 
standard culture medium compared with CAF-CM in 
the presence of both oxaliplatin and 5FU. This suggests 
a premature G2/M transition to overcome a deficient 
checkpoint control (Figure 2c).
Table 1: Percentage of necrotic cells (mean of three independent experiments) measured at different times after drug 
administration by flow cytometry (propidium iodide staining) in cells cultured with standard DMEMF12 or CAF-
conditioned media
HT29 cells DLD-1 cells











No drug 11.16 10.77 21.5 21.5 6.24 5.5 9.61 10.3 13.5 9.3
5FU 2x 13.41 15.6 87 60.9* 6.7 4.8 7.6 7.7 13.7 9.3
5FU 4x 20.45 25 94.92 86* 6.1 6.1 8.1 11.1 21.3 19.1
L-OHP 
2x
9.48 9.7 39.6 35.3 4.3 4.4 17.6 8.8* 34 17.8*
L-OHP 
4x
11.4 10.5 42.1 32.2* 5.04 4.4 16.8 9.6* 64.2 40.3*
5FU and L-OHP were administered 24 hours after seeding at 2× or 4× IC50 of each cell type (*P<0.05, Mann-Whitney U 
statistic).
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Figure 2: a. and b. CHK2 phosphorylation (Thr68) in the presence of CAF-CM upon oxaliplatin and 5FU administration for 24 and 48 hours in 
DLD-1 (A) and HCT116 (B) cell lines, respectively. c. Overexpression of CDC25B in DLD-1 cells treated with standard medium (DMEMF12) 
in the presence of drugs for 24 and 48 hours. d and e. AKT and STAT3 were phosphorylated after drug exposure (1 and 3 hours) in the presence 
of CAF-CM in DLD-1 and HCT116, respectively. f. mTORSer2448 and P38 were also differentially phosphorylated after CAF-CM treatment 
relative to standard medium and Survivin western blot analysis. Survivin was differentially overexpressed after culturing cells with CAF-CM. 
g. Protein extracts from nuclear and cytosolic fractions of HT29 cells treated with 5FU for 24 hours and 72 hours. We observed pAKT nuclear 
translocation in cells cultured in conditioned media from CAFs. Survivin was basically translocated in both standard medium and CAF-CM, 
although we observed overexpression under the influence of soluble factors from CAFs. h. Similarly, nuclear translocation of active P38 of HT29 
cells was observed after 24 hours and 72 hours of treatment in the presence of CM-CAFs. i. A slight increase of MAPKAP2 phosphorylation, a 
P38 downstream kinase, was noted in HT29 cells after CAF-CM treatment. j. Cyclin D1 and Cyclin D3 expression in the presence of oxaliplatin 
and 5FU in HT29 cultured in DMEMF12 and CM-CAFs for 24 hours and 48 hours. Cyclin D1 was overexpressed in the presence of CM-CAFs 
in oxaliplatin and 5FU treatments. On the other hand, there was an inverse correlation between Cyclin D1 and Cyclin D3 expression levels, as 
previously reported (Zhang, P. et al BMC Cancer 2006, 15(6):224). k. HT29 and oxaliplatin-resistant derivative (HTOXAR3) cell lines cultured 
in the absence of drugs. In the resistant-derivative cells, pAKT, pP38, STAT3 and Survivin were overexpressed relative to sensitive cells.
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CAF-conditioned media stimulate AKT, Survivin 
and P38 nuclear translocation
It is well known that AKT is crucial to overcoming 
the G2/M cell cycle checkpoint after DNA damage. In 
addition, the PI3KCA/AKT/mTOR/Survivin pathway 
has been associated with 5FU, cisplatin and resistance to 
other DNA-damaging agents in many types of cancer. In 
evaluating the phosphorylation of AKT, we observed an 
increase in cells cultured with CAF-CM compared with 
DMEMF12 for DLD-1 (Figure 2d) and HCT116 (Figure 
2e) exposed to 5FU or L-OHP. This result might be 
predictable, since the large quantity of ligands secreted by 
CAFs that activated the PI3KCA/AKT pathway as well 
as JAK/STAT, a cytokine-addicted pathway. Additionally, 
phosphorylation of Ser2448 mTOR, P38 activation and 
overexpression of Survivin were also evidenced in cells 
cultured with CAF CM (Figure 2f).
We also explored the AKT and Survivin subcellular 
localization. We observed sustained AKT phosphorylation 
in the nucleolus of cells cultured in CAF-CM (Figure 
2g). This is accompanied by the nuclear translocation 
of Survivin and P38 (Figure 2h), which occurs more 
efficiently in cells under the influence of CAF-soluble 
factors. AKT, Survivin and P38 nuclear translocation 
were corroborated in different cell lines and treatments 
by immunofluorescence (Figures 3, 4 and Supplementary 
Figures S3 and S4a). Subconfluent continuous cell cultures 
also showed an increase in P38 downstream kinase 
MAPKAP2 when cells were exposed to CAF-conditioned 
media (Figure 2i). Additionally, the administration of a 
P38 inhibitor (VX-702) sensitizes colorectal cancer cells 
to oxaliplatin and 5FU (Supplementary Figure S4b).
We also checked the expression of Cyclin D1, as a 
common downstream effector of JAK/STAT and PI3KCA/
AKT pathways, inducer of chemoresistance in many 
tumor types and essential for cell cycle progression. As 
illustrated in Figure 2j, cyclin D1 was overexpressed in 
cells cultured in CM. Additionally, there was an inverse 
correlation with the levels of cyclin D3 also reported by 
Zhang P et al [20] in relation to cisplatin sensitivity.
All the events described so far seem to involve 
some factors secreted by CAFs in mediating de novo 
chemoresistance to L-OHP and 5FU. All the studied 
pathways are also overstimulated in cells with acquired 
resistance, as depicted in Figure 2k, suggesting that there 
is a degree of convergence between stroma-mediated and 
genetically acquired resistance.
STAT3 silencing sensitizes cells to oxaliplatin 
and 5FU. Pharmacological inhibition of AKT 
antagonizes with chemotherapy
We have previously shown that CAF-CM can 
shift the IC50 curves for 5FU and oxaliplatin even in 
genetically determined oxaliplatin-resistant HTOXAR3 
cells. Additionally, ligands present in CAF-CM were 
particularly efficient in activating JAK/STAT and AKT 
pathways, as shown in Supplementary Figure S5 and S6. 
Thus we decided first to check whether STAT3 inhibition 
could bypass the effect triggered by soluble factors 
released by CAFs. Stable silencing of the transcription 
factor by means of shRNA revealed that cells were more 
sensitive to oxaliplatin even in the presence of CAF’s CM, 
where different JAK/STAT activators are present (Figure 
5a). Interestingly, levels of Survivin were also decreased 
in STAT3 deficient cells (Figure 5b). In addition, the 
STAT3 silencing was also efficient sensitizing oxaliplatin-
resistant cells (HTOXAR3), to both oxaliplatin and 5FU in 
different experimental conditions with JAK/STAT ligands 
(Figure 5c and 5d).
Pharmacological inhibition of AKT antagonizes 
with chemotherapy
Furthermore, we also examined whether the 
pharmacological inhibition of AKT with MK2206, a 
highly selective allosteric AKT inhibitor, could also 
overcome the effect induced by CAF-CM.
Astonishingly, MK2206 seems to have an 
antagonistic effect with L-OHP and 5FU even at different 
doses tested (IC5 and IC50) for the two conditions 
tested (Figure 6a and 6b). The combination index values 
(>1) confirmed the antagonistic effect of MK2206 with 
oxaliplatin (Figure 6c) and for 5FU (Figure 6f). In addition 
there is a high correlation between the dose of MK2206 
and the increase of the IC50 values for chemotherapeutic 
agents (Figure 6e).
We suspected that these observations could be due 
to compensatory mechanisms that are the consequence 
of inhibiting a crucial oncogenic pathway like PI3K/
AKT. The expression of MYC and RTK (particularly 
IGF1R, EGFR and ERBB3) is involved in compensatory 
mechanisms after PI3K/AKT inhibition [21–24]. After 24 
hours of treatment we observed potent AKT inhibition 
even at very low doses (100 nM; Figure 6g), confirming 
the efficacy of the inhibitor. Interestingly, although we 
did not observe overexpression of previously reported 
RTK or MYC, a compensatory feedback loop seems 
to me mediated by JAK/STAT pathway, regarding the 
overexpression of JAK1 and hyperactivation of STAT3 
according to the dose increase of AKT inhibition (Figure 
6g).
DISCUSSION
While many research publications have described 
cell-autonomous processes playing decisive roles in 
mediating acquired resistance to chemotherapy, little is 
known about the influence of the tumor microenvironment 
on responses to chemotherapy.
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The present study showed how soluble factors 
secreted by CAFs trigger a cell signaling cascade 
that protects cells from the action of conventional 
chemotherapy used in colorectal cancer treatment, a 
process involving the nuclear translocation of AKT and 
P38 and the activation of the JAK/STAT pathway.
It is intuitive that cytokines, chemokines and growth 
factors secreted in large quantities by CAFs will activate 
signaling cascades mainly through the PI3KCA/AKT 
and JAK/STAT pathways, and that such signaling is a 
requisite and a key event for cell proliferation, migration 
and invasion [25, 26]. However, these pathways are also 
relevant for cell cycle regulation, survival and DNA repair 
[27, 28, 29, 30, 31, 32].
Our results confirmed that the PI3K-AKT and JAK-
STAT pathways were overexpressed in the presence of 
Figure 3: Localization of pAKT assessed by immunofluorescence. HT29, DLD-1 and HCT116 cell lines were treated with 5FU 
in the presence of DMEMF12 or CM-CAFs. The nuclear translocation of pAKT occurs in the treatments where soluble factors from CAFs 
were present, while, in DMEMF12 treatments, pAKT was mainly founded predominantly in cytosolic areas.
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conditioned media from CAFs, even in the presence of 
5FU or oxaliplatin administration. However, the location of 
activated AKT is crucially important for such a protective 
effect conferred by CAF-soluble factors. Once activated, 
different AKT isoforms translocate to diverse subcellular 
compartments to exert specific functions depending on the 
location [27]. Nuclear translocation of AKT during G1 in 
particular has been associated with cell cycle progression 
[33], Cyclin D1 expression [34] and DNA repair after 
double-strand breaks (DSBs) [35]. Additionally, different 
growth factors and soluble molecules have been reported 
to induce nuclear translocation of AKT (e.g., IGF1, 
insulin and NGF) [36, 37, 38]. In the context of our 
results, soluble factors secreted by CAFs induce nuclear 
AKT translocation that might provide protection from 
cell death, ensuring correct DNA repair and triggering 
Figure 4: Localization of pAKT assessed by immunofluorescence. HT29, DLD-1 and HCT116 cell lines were treated with 
oxaliplatin in the presence of DMEMF12 or CM CAFs. pAKT is translocated to the nuclei in the presence of conditioned media from CAFs. 
However, in DMEMF12 treatments, pAKT was predominantly located in the cytosol.
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Figure 5: STAT3 was silenced in HT29 cells and oxaliplatin-resistant HT29 derivatives (HTOXAR3) by using shRNA. 
STAT3-silenced HT29 cells were more sensitive to both oxaliplatin a. and 5FU (data not shown) than wild-type and non-silencing HT29 
cells. The silencing also affected STAT3 target genes like BIRC5 according to the decrease levels of Survivin in these STAT3-silenced cells 
b. In addition the STAT3 silencing was also effective in cells with genetically determined acquired resistance to L-OHP like HTOXAR3 
cells as shown in dose-response curves (panel c. and 5FU panel d. using standard conditions (DMEMF12) or particular stimulation of JAK/
STAT pathway (supplemented with IL6 [10 ng/ml]) or different signaling pathways with CAF’s CM. Successful silencing of total STAT3 
was also demonstrated by western blot analysis in continuous subcultures of HTOXAR3 cells in CAF-CM e.
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Figure 6: Dose-response curves for Oxaliplatin in HT29 cells cultured in DMEMF12 a. and CAF-CM b. in combination 
with AKT inhibitor MK2206 at IC5 and IC50 doses as single agent (500 nM or 2100 nM). c. The integrated dose-reduction 
(left Y axis) and Fa-combination index (right Y axis) plots show that combination index is >1, indicating the antagonistic effect of the 
combination and the increase of L-OHP concentration needed for different IC’s when adding AKT inhibitor both culturing cells with 
standard medium (black lines) or CAF’s CM (red lines), same observation also shown as histograms d. Dose-response curves of HTOXAR3 
cells (oxaliplatin-resistant HT29 derivative) for oxaliplatin and oxaliplatin plus different concentrations of MK2206, illustrating the shift in 
IC50 curves associated with the antagonistic effect, the more AKT inhibitor, the more oxaliplatin to kill the 50% of cells e. The same results 
than in (a) and (b) were obtained for 5FU f. Immunoblots from HTOXAR3 cells cultured for 24 hours with various doses of MK2206. AKT 
was clearly inhibited even at very low doses (100 nM). No RTK (EGFR or IGF1R) or MYC expression changes were observed, contrary to 
what has been reported in other tumor types. However, we observed an inverse correlation in overexpression of JAK1 and MET in relation 
to the concentration of the AKT inhibitor. This seems to be accompanied by activation of STAT3 as a compensatory mechanism g.
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cell cycle arrest to strictly control the G2/M transition 
caused by the increased levels of CHK2 phosphorylation 
in CAF-CM-cultured colorectal cancer cells. Conversely, 
cells grown without the contribution of cytokines and 
growth factors provided by the fibroblasts, in the presence 
of DNA-damaging agents, cannot efficiently repair the 
damaged DNA since the checkpoint control does not work 
properly. The elevated levels of CDC25B boost entry into 
mitosis without ensuring genome integrity. Our cell cycle 
analyses corroborate this. Therefore, the decision of cells 
to remain in the G2/M phase or to go through defective 
mitosis is favored by microenvironmental factors, 
enhancing both the nuclear translocation of AKT and the 
phosphorylation of CHK2. Furthermore, DNA damage-
induced activation of CHK2 results in Survivin trafficking 
from the mitochondria to the cytosol, inducing the 
inhibition of apoptosis and promoting tumor cell survival 
[15]. In our experiments there was no suggestion that cells 
were dying by apoptosis. In fact, we clearly observed that 
cells developed a necrotic pattern after long-term exposure 
to both oxaliplatin and 5FU. This finding, in combination 
with the cytometric cell cycle analysis, led us to conclude 
that the higher levels of Survivin detected in whole-cell 
extracts of cells cultured with CAF CM might control 
processes other than apoptosis.
It has already been reported that Survivin can 
be located in different subcellular pools inside the cell, 
cytosol, mitochondria and nucleus [39]. These subcellular 
pools, as AKT, are believed to be strongly tied to its 
varying cellular functions. Studies have demonstrated 
that the nuclear pool mediates Survivin function in 
mitosis, while the cytosolic and mitochondrial fractions 
are responsible for its antiapoptotic function [40]. 
When we assessed the levels of Survivin in nuclear and 
cytoplasmic extracts we observed that almost all Survivin 
was translocated to the nuclei in cells cultured with CAF-
CM. In addition, Survivin associates with microtubules to 
contribute to the correct assembly of chromosomes during 
the spindle formation [41]. Survivin can also repress cell 
death in mitotic cells, preventing mitotic catastrophe [42]. 
Our results suggest that nuclear AKT and STAT3 might 
regulate Survivin, as reported in platinated agents like 
cisplatin [43] and for 5-fluorouracil [44]. In fact, different 
cytokines and growth factors like IL6, IGF1 and CCL2 
are known inducers of Survivin overexpression in a PI3-
kinase/AKT or JAK/STAT dependent process [44–46]. 
The consequence is that many cells die during mitosis 
or divide inaccurately, dying in the next division or 
generating instability, as found in colorectal cancer cells 
exposed to anti-mitotic drugs [14].
Another event that is closely related to the 
mechanism detailed above is the translocation of P38 
MAPK to the nucleus in cells cultured in CAF-CM, which 
occurs more efficiently than in standard culture medium. 
In response to DSBs induced by DNA-damaging agents, 
P38 is activated to control the G2/M checkpoint [47] 
and is translocated to the nucleus. Therefore, cytokines/
chemokines or other soluble factors secreted by CAFs 
may enhance the nuclear translocation of P38 MAPK in 
tumor cells to facilitate the phosphorylation of P38 nuclear 
targets necessary for the induction of the appropriate 
G2/M cell cycle checkpoint and correct DNA repair in 
those cells carrying DSBs.
From the point of view of the functional assays, 
as a consequence of the signaling described, CRC 
cells cultured in CAF-CM seem to be less sensitive 
to chemotherapy, shifting IC50 curves to a greater 
extent than NCF-CM compared with standard culture 
medium, making it a cause of chemoresistance. All these 
mechanisms give rise to a slower proliferative rate, even 
in the absence of DNA-damaging agents, as determined 
by MTT assays, hemocytometer counting and prolonged 
G1 phase in a flow cytometric cell cycle assessment. This 
is in line with the fact that the subtype of colorectal cancer 
tumors that is most enriched in stromal components, and 
fibroblasts in particular, are less proliferative, overexpress 
Survivin, displayed fewer genetic alterations [48–50], 
qualities involved in chemoresistance. These are features 
that we observed culturing CRC cells in CAF-CM.
In addition we can not ascribe the observations and 
mechanisms described here to a single factor secreted 
by CAFs. These cells synthesize a large amount of 
different redundant cytokines and growth factors, most of 
them activating ligands of JAK/STAT or PI3KCA/AKT 
pathways.
Different strategies, like STAT3 silencing or AKT 
and P38 inhibition have been employed to diminish 
microenvironment-mediated drug resistance. These 
pathways are also involved and constitutively activated 
in acquired-resistance processes, suggesting convergence 
of stroma-induced and genetically determined resistance. 
The inhibition of STAT3 and P38 sensitizes cells to 
chemotherapy, while the inhibition of AKT elicits a 
compensatory feedback mechanism that appears to be 
mediated by the overexpression of Met and activation of 
STAT3 that may explain the failure of AKT inhibitors.
In conclusion, we report here that cytokines, 
chemokines and other soluble factors secreted by CAFs 
induce nuclear translocation of selected effectors that 
in turn slow the progress of the cell cycle, thereby 
affecting proliferation. In the presence of conventional 
chemotherapy, such effectors permit the stabilization and 
activation of selected downstream proteins that ensure 
correct DNA repair and correct mitosis entrance and 
exit, avoiding the damage induced by such agents. From 
a clinical perspective, our study provides information of 
use in assessing the preclinical value of STAT3 and P38 
inhibition in chemotherapy-sensitizing strategies designed 
to overcome microenvironment-mediated resistance. 
Identifying the soluble factors that mediate such 
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events might yield valuable information to circumvent 
microenvironmentally-mediated drug resistance, although 
the compensatory loops and redundancy of many such 
cytokines for the same signaling pathways might give 
rise to new resistant phenotypes. Hampering key common 
proteins responsible for the synthesis of such cytokines/
growth factors in CAFs might be an interesting approach 
to avoid the protective effect exerted by such molecules 
and to render tumor cells sensitive to chemotherapy.
MATERIALS AND METHODS
All the experiments were performed under the 
approval of the IDIBELL’s Ethics Committee. Samples for 
fibroblast isolation were obtained under patient’s informed 
consent.
Fibroblast culture and conditioned media 
acquisition
The fibroblasts were isolated and the conditioned 
media (CM) were obtained as described previously [11].
Colorectal cancer cell lines
DLD1 (MSI positive, chromosomal instability 
pathway negative, Kras mutated, PI3KCA mutated, TP53 
mutated), HCT116 (MSI positive, chromosomal instability 
pathway negative, Kras mutated, PI3KCA mutated, TP53 
wild type), HT29 (MSS, chromosomal instability pathway 
positive, Braf mutated, PI3KCA mutated, TP53 mutated), 
HTOXAR3 (HT29 oxaliplatin-resistant derivative; 
transcriptionaly characterized in GSE10405).
Cell proliferation
WST-1 proliferation assay was performed following 
manufacturer instructions. Previously, 2000 cells/well 
(HT29, HTOXAR3, DLD-1, HCT116; all cell lines were 
obtained from our own cryobank except the oxaliplatin-
resistant derivative HTOXAR3, kindly provided by Dr. 
E.M.Balibrea) were plated in six replicative wells in 96-
well plates and allowed to attach, then grown in DMEM 
F12 at 37°C overnight. Next day, drugs were added in 
standard media or fibroblast CM. The cells were incubated 
for 5 days. The effect of the drug on each cell line in the 
presence or absence of CM was calculated by normalizing 
the number of cells after 5 days of continuous treatment to 
the maximum number of cells in each treatment (standard 
DMEMF12 medium, normal colonic fibroblast-CM [NCF-
CM] or CAF-CM).
Cell cycle analysis
The cell cycle was assessed by conventional PI 
staining.
The samples analyses were performed in a Gallios 
Flow Cytometer and the generated data analyzed using 
FCS Express Analysis Software (de Novo software).
Colony formation assay
1×103 CRC cells were plated in 60-mm culture 
dishes (or 2×102 in 6-well plates) and incubated at 37°C. 
After overnight incubation, treatments were added 
and incubated for 2 weeks. The clones were fixed with 
methanol for 2 minutes, stained with 0.5% crystal violet 
and incubated at room temperature for 20 minutes. The 
cells were washed to remove staining exceeded. Colonies 
were defined from counts of at least 50 cells.
Immunofluorescence staining
The cells were seeded in coverslip slides on 6-well 
plates, fixed with paraformaldehyde (PFA) 4% for 20 
minutes and washed 3 times with PBS 1×, permeabilized 
with PBS 1× 0.1% Triton X-100 at room temperature for 
5 minutes and blocked with BSA 2% for 45 minutes–2 
hours. Cells were incubated with primary antibody in 
BSA 2% in a dilution 1:50 overnight and then incubated 
with 1:200 fluorescence secondary antibody in BSA 2% 
for 1 hour at room temperature. Coverslip slides were 
mounted in VectaShield with DAPI (Vector Laboratories, 
Burlingame, USA).
Western blot analysis
Protein concentration was determined by the BCA 
Protein Assay (Pierce, Rockford, IL, USA). 30 μg of the 
protein extract was subjected to sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE), and 
transferred to PVDF membranes. After blocking for 1 
hour with 5% dried non-fat milk in TBS 1× - Tween 0.1%, 
the membranes were incubated with primary antibody 
diluted 1:1000 in 1% bovine serum albumin (BSA) in 
TBS 1× - Tween 0.1%. Antibody binding was detected 
using a secondary antibody diluted 1:2000 in TBS 1× 
- Tween 0.1% and an enhanced chemiluminescence 
(ECL) detection kit (Amersham, Buckinghamshire, 
UK). α-tubulin expression was used as an endogenous 
control. A general protocol for nuclear and cytosolic 
fractions separation was used. Briefly, cells were washed 
twice in PBS and scrapped in 300 μl of cytoplasmic lysis 
buffer containing 10 mM HEPES pH 7.4, 10 nM KCl, 
0.01 mM EDTA, 0.1 mM EGTA, 2 mM dithiothreitol, 
5 mM Na2VO4, 20 mM sodium beta-glycerophosphate, 
0.1% Nonidet P-40, and a cocktail of protease inhibitors 
(Roche). Nuclei were sedimented by centrifugation and the 
supernatant containing the cytoplasmic fraction removed. 
The nuclei were then washed in 1 ml of cytoplasmic 
lysis buffer to remove any contaminating cytoplasm 




In order to assess necrosis or apoptosis by flow 
cytometry and immunofluorescence, cells were stained 
with the Promokine apoptotic/necrotic/healthy cell 
detection kit (cat #PK-CA707-30018, PromoCell, 
Heidelberg, Germany). First, the cells were detached 
from the cell culture plate using StemPro Accutase 
Cell Dissociation Reagent (cat #A1110501, Thermo 
Scientific), washed twice with 1X binding buffer and 
then incubated for 15 minutes at room temperature with 
staining solution (5 μL of FITC-Annexin V, 5 μL of 
Ethidium Homodimer III and 5 μL of Hoechst 33342 
to 100 μL of 1× binding buffer). Cells were washed 1-2 
times and mounted on a slide for microscope viewing, 
or resuspended in 400 μL in 1× binding buffer and 
then sent for flow cytometry analysis within 1 hour of 
staining in a Gallios Flow Cytometer (Beckman Coulter, 
Krefeld, Germany).
The Ac-DEVD-AMC Caspase-3 fluorogenic assay 
(BD Biosciences Pharmingen, San Agustin de Guadalix, 
Madrid, Spain) was performed to assess caspase-
dependent apoptosis. Whole cellular extract (adherent 
cells and floating cells) was recovered with lysis buffer 
and, subsequently, 20 μM of Ac-DEVD-AMC and the 
cell lysate were replaced by 1 mL of protease assay 
buffer (described in the manufacturer’s instructions). The 
reaction mixtures were incubated for 2 hours at 37°C in 
the dark and then measured at wavelengths of 380 nm 
excitation and 430-460 nm emission.
Immunofluorescence of cleaved caspase 3 was also 
carried out.
Chemicals
MK-2206 2HCl (AKT inhibitor) and VX-702 
(P38 inhibitor) were purchased from Selleck Chemicals 
(Houston, TX, USA) and dissolved in DMSO as a stock 
solution. CRC cells were seeded at a density of 2000/4000 
cells per well in 96-well plates and incubated with 
DMEMF12 overnight. Inhibitors were then added to the 
cells in combination with 5FU or oxaliplatin.
Silencing STAT3 by lentiviral shRNA
GIPZ lentiviral shRNA (cat #V3LHS_641817 
and #V3LHS_641819 clones purchased from Thermo 
Scientific) was used to establish STAT3 knockdown 
in HTOXAR3 colorectal cell lines. Glycerol-stored 
plasmid was previously replicated, isolated, transfected 
in HEK293T cells and finally transduced in target cells. 
Cells were selected, according to kill curve values, with 
puromycin (2 μg/ml). A non-silencing GIPZ lentiviral 
shRNA containing a random vector was used as a control 
in both cell lines in subsequent experiments. Western blot 
was performed to confirm STAT3 silencing efficiency in 
colorectal cell lines.
Statistical analysis
Data from independent experiments were 
statistically analyzed using the nonparametric Mann-
Whitney U test to compare group differences between 
experimental and control samples at a level of significance 
of P<0.05. Extra sum-of-squares F test was carried out 
in GraphPad PRISM 6 (GraphPad Software, San Diego, 
California, USA) to identify statistically significant 
differences (P<0.05) between IC50 curves.
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